Recently, a murine model of colorectal cancer was used to explore whether TEX-miR-34a can serve as a favourable therapeutic option in CRC combinational therapies, one function of which is inhibiting angiogenesis by targeting VEGF [122]. This evidence concerns the gene VEGFA and colorectal carcinoma.